Evidence map›Paper›PMID 31819404›Full record

ArticleInternational journal of chronic obstructive pulmonary disease2019

Clinical Outcomes Of Using Nebulized Budesonide As The Initial Treatment For Acute Exacerbations Of Chronic Obstructive Pulmonary Disease: A Post-Hoc Analysis.

Jin-Ping Zheng, Jing Zhang, Li-Jun Ma, Ping Chen, Mao Huang, Xue-Mei Ou, Zi-Wen Zhao, Shu-Juan Jiang, Jie Cao, Wanzhen Yao

Registry-linked trialOpen access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of chronic obstructive pulmonary disease, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02051166 (A Non Interventional, Retrospective Study on AECOPD Treatment Status in China), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02051166 completednot on this map

A Non Interventional, Retrospective Study on AECOPD Treatment Status in China

TypeobservationalSponsorAstraZenecaRan2014 to 2014Enrolled5,095ConditionsAcute Exacerbation of Chronic Obstructive Pulmonary Disease
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Nebulized corticosteroidsFrontiers in pharmacology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 10 institutions in 1 country.

Jin-Ping Zheng *State Key Laboratory of Respiratory Disease, National Clinical Research Center, Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People's Republic of China.
Jing Zhang *Department of Respiratory Medicine, Peking University Third Hospital, Beijing, People's Republic of China.
Li-Jun MaDepartment of Respiratory Medicine, Henan Provincial People's Hospital, Henan, People's Republic of China.
Ping ChenDepartment of Internal Medicine, The Second Xiangya Hospital, Hunan, People's Republic of China.
Mao HuangJiangsu Province Hospital, Jiangsu, People's Republic of China.
Xue-Mei OuDepartment of Respiratory Medicine, West China Hospital, Chengdu, People's Republic of China.
Zi-Wen ZhaoDepartment of Respiratory Medicine, Guangzhou First People's Hospital, Guangzhou, People's Republic of China.
Shu-Juan JiangDepartment of Respiratory Medicine, Shandong Provincial Hospital, Shandong, People's Republic of China.
Jie CaoDepartment of Respiratory Medicine, Tianjin Medical University General Hospital, Tianjin, People's Republic of China.
Wanzhen YaoDepartment of Respiratory Medicine, Peking University Third Hospital, Beijing, People's Republic of China.
Central South University · CNGuangzhou Medical University · CNHenan Provincial People's Hospital · CNJiangsu Province Hospital · CNPeking University · CNPeking University Third Hospital · CNShandong Provincial Hospital · CNState Key Laboratory of Respiratory Disease · CNTianjin Medical University General Hospital · CNWest China Hospital of Sichuan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: The current guidelines recommend the use of systemic corticosteroids (SCS) as the optimal treatment for acute exacerbations of chronic obstructive pulmonary disease (AECOPD). The aim of this real-world study was to evaluate whether nebulized budesonide (NBS) could also be used as an initial treatment for AECOPD. Patients and methods: AECOPD patients initially treated with NBS or SCS (oral/intravenous) were enrolled. A large-scale, long-term multicenter cohort study of AECOPD patients was performed to analyze outcomes for each treatment (NCT02051166). Results: Initial NBS and SCS treatment resulted in similar outcomes in terms of improvements in FEV Conclusion: These results indicate that NBS may be used as an initial treatment in certain AECOPD patients, and further studies are needed to better define those most likely to benefit.

Indexed as

Administration, InhalationAgedAged, 80 and overBronchodilator AgentsBudesonideChinaDisease ProgressionFemaleForced Expiratory VolumeGlucocorticoidsHumansLungMaleMiddle AgedNebulizers and VaporizersPulmonary Disease, Chronic ObstructiveBronchodilator AgentsBudesonideGlucocorticoidsAECOPDchronic obstructive pulmonary diseasenebulized budesonidesystemic corticosteroids

Identifiers

PMID31819404
PMCPMC6889964
OpenAlexW2993202963

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.